Provided by Tiger Trade Technology Pte. Ltd.

iShares Global Healthcare ETF

102.05
-0.1100-0.11%
Volume:154.58K
Turnover:15.83M
Market Cap:4.19B
PE:-99.24
High:102.70
Open:102.36
Low:101.75
Close:102.16
52wk High:107.69
52wk Low:85.36
Shares:41.10M
Float Shares:41.10M
Volume Ratio:0.42
T/O Rate:0.38%
Dividend:1.38
Dividend Rate:1.35%
EPS(TTM):-1.0283
EPS(LYR):-1.0283
ROE:-8.66%
ROA:0.90%
PB:1.08
PE(LYR):-99.24

Loading ...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)

TIPRANKS
·
Sep 11

MS Cuts Novo Nordisk on Growth Prospects, Patent Expiry Risks

Reuters
·
Sep 11

Growth Without AI: 8 Stock Picks

Dow Jones
·
Sep 11

Vita Life Sciences Updates Market on Progress of On-Market Share Buy-Back

TIPRANKS
·
Sep 11

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 11

TransMedics Group Names New Chief Financial Officer

TIPRANKS
·
Sep 11

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 11

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
Sep 11

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
Sep 11

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
Sep 11

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
Sep 11

Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout

Reuters
·
Sep 10

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Reuters
·
Sep 10

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10